Cell MedX elects four directors and increases authorized shares to 7.5B

Stimcell Energetics Inc.

Elected directors: David Jeffs, George Adams, Joao (John) Da Costa, Amir Vahabzadeh effective April 1, 2024.
Authorized common stock increased from 300M to 7.5B shares ($0.001 par value).
Increase approved by written consent of stockholders holding 66% of outstanding shares.
No other material corporate changes were disclosed in the filing.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Stimcell Energetics Inc.: Increase in authorized capital from 300,000,000 to 7,500,000,000 shares of common stock (effective 2024-04-01).

Change: charter amendment
Effective: 2024-04-01

Exact text from the filing

On April 1, 2024, Cell MedX Corp. (the “Company”), amended its articles of incorporation to increase the authorized capital of the Company from 300,000,000 shares of common stock, par value $0.001 (the “Common Stock”) to 7,500,000,000 shares of Common Stock (the “Increase in Authorized Capital”).

View on SEC.gov

Browse all governance changes →

Stimcell Energetics Inc. filing history →

Source: SEC EDGAR

accession 0001393905-24-000114

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.